<akomaNtoso xmlns:uk="https://www.legislation.gov.uk/namespaces/UK-AKN" xmlns:ukl="http://www.legislation.gov.uk/namespaces/legislation" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0" xsi:schemaLocation="http://docs.oasis-open.org/legaldocml/ns/akn/3.0 http://docs.oasis-open.org/legaldocml/akn-core/v1.0/cos01/part2-specs/schemas/akomantoso30.xsd"><act name="eur"><meta><identification source="#"><FRBRWork><FRBRthis value="http://www.legislation.gov.uk/id/eur/2016/1933"/><FRBRuri value="http://www.legislation.gov.uk/id/eur/2016/1933"/><FRBRdate date="2016-11-04" name="adopted"/><FRBRauthor href=""/><FRBRcountry value="EU"/><FRBRnumber value="1933"/><FRBRname value="Regulation (EU) 2016/1933"/><FRBRprescriptive value="true"/></FRBRWork><FRBRExpression><FRBRthis value="http://www.legislation.gov.uk/eur/2016/1933/2016-11-04"/><FRBRuri value="http://www.legislation.gov.uk/eur/2016/1933/2016-11-04"/><FRBRdate date="2016-11-04" name="validFrom"/><FRBRauthor href="#"/><FRBRlanguage language="eng"/></FRBRExpression><FRBRManifestation><FRBRthis value="http://www.legislation.gov.uk/eur/2016/1933/2016-11-04/data.akn"/><FRBRuri value="http://www.legislation.gov.uk/eur/2016/1933/2016-11-04/data.akn"/><FRBRdate date="2026-08-25+01:00" name="transform"/><FRBRauthor href="http://www.legislation.gov.uk"/><FRBRformat value="application/akn+xml"/></FRBRManifestation></identification><lifecycle source="#"><eventRef refersTo="#adopted" date="2016-11-04" eId="date-adopted" source="#"/><eventRef date="2016-11-04" eId="date-2016-11-04" source="#"/></lifecycle><analysis source="#"><restrictions source="#"><restriction refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#preface" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#body" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#article-1" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#article-2" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#body-signatures" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#schedules" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction href="#annex" refersTo="#extent-e+w+s+ni" type="jurisdiction"/><restriction refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#preface" refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#body" refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#article-1" refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#article-2" refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#body-signatures" refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#schedules" refersTo="#period-from-2016-11-04" type="jurisdiction"/><restriction href="#annex" refersTo="#period-from-2016-11-04" type="jurisdiction"/></restrictions><otherAnalysis source=""/></analysis><temporalData source="#"><temporalGroup eId="period-from-2016-11-04"><timeInterval start="#date-2016-11-04" refersTo="#"/></temporalGroup></temporalData><references source="#"><TLCEvent eId="adopted" href="" showAs="AdoptedDate"/><TLCLocation eId="extent-e+w+s+ni" href="/ontology/jurisdictions/uk.EnglandWalesScotlandNorthernIreland" showAs="E+W+S+N.I."/></references><proprietary xmlns:ukm="http://www.legislation.gov.uk/namespaces/metadata" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" source="#"><dc:identifier>http://www.legislation.gov.uk/eur/2016/1933</dc:identifier><dc:title>Commission Implementing Regulation (EU) 2016/1933 of 4 November 2016 approving calcium magnesium tetrahydroxide (hydrated dolomitic lime) as an existing active substance for use in biocidal products of product-types 2 and 3 (Text with EEA relevance)</dc:title><dct:alternative>Commission Implementing Regulation (EU) 2016/1933</dct:alternative><dc:description>Commission Implementing Regulation (EU) 2016/1933 of 4 November 2016 approving calcium magnesium tetrahydroxide (hydrated dolomitic lime) as an existing active substance for use in biocidal products of product-types 2 and 3 (Text with EEA relevance)</dc:description><dc:modified>2020-12-12</dc:modified><dc:publisher>King's Printer of Acts of Parliament</dc:publisher><dc:source>https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R1933</dc:source><dc:type>text</dc:type><dc:format>text/xml</dc:format><dc:language>en</dc:language><dct:valid>2016-11-04</dct:valid><ukm:EUMetadata><ukm:DocumentClassification><ukm:DocumentCategory Value="euretained"/><ukm:DocumentMainType Value="EuropeanUnionRegulation"/><ukm:DocumentStatus Value="revised"/></ukm:DocumentClassification><ukm:Year Value="2016"/><ukm:Number Value="1933"/><ukm:EURLexIdentifiers xmlns:atom="http://www.w3.org/2005/Atom" xmlns="http://www.legislation.gov.uk/namespaces/legislation"><ukm:Cellar Value="fb5bd2e7-a2e8-11e6-8401-01aa75ed71a1"/><ukm:OfficialJournal Value="JOL_2016_299_R_0007"/><ukm:CELEX Value="32016R1933"/><ukm:ELI Value="reg_impl:2016:1933:oj"/></ukm:EURLexIdentifiers><ukm:EnactmentDate Date="2016-11-04"/><ukm:EURLexModified Date="2017-04-07T05:35:50Z"/><ukm:EURLexExtracted Date="2018-05-21T13:09:02Z"/><ukm:XMLGenerated Date="2020-12-12T17:42:29Z"/><ukm:XMLImported Date="2020-12-12T23:38:27Z"/><ukm:Treaty Title="Treaty on the Functioning of the European Union (consolidated version 2012)" Code="TFEU_2012"/><ukm:CreatedBy Label="European Commission" URI="http://publications.europa.eu/resource/authority/corporate-body/COM"/><ukm:Subject Scheme="EuroVoc" Label="market approval" URI="http://eurovoc.europa.eu/5451"/><ukm:Subject Scheme="EuroVoc" Label="pharmaceutical product" URI="http://eurovoc.europa.eu/2773"/><ukm:Subject Scheme="EuroVoc" Label="decontamination" URI="http://eurovoc.europa.eu/2877"/><ukm:Subject Scheme="DirectoryCode" Label="Other sectors for approximation of laws" URI="http://publications.europa.eu/resource/authority/fd_555/133099"/><ukm:Subject Scheme="DirectoryCode" Label="Internal market: approximation of laws" URI="http://publications.europa.eu/resource/authority/fd_555/1330"/><ukm:Subject Scheme="DirectoryCode" Label="Industrial policy and internal market" URI="http://publications.europa.eu/resource/authority/fd_555/13"/><ukm:Subject Scheme="EuroVoc" Label="chemical product" URI="http://eurovoc.europa.eu/2739"/><ukm:Subject Scheme="SubjectMatter" Label="Internal market - Principles" URI="http://publications.europa.eu/resource/authority/fd_070/MARI"/><ukm:Subject Scheme="EuroVoc" Label="animal welfare" URI="http://eurovoc.europa.eu/5462"/><ukm:DocumentCurrentStatus><ukm:UKAmended Value="false"/></ukm:DocumentCurrentStatus></ukm:EUMetadata><ukm:Alternatives><ukm:Alternative URI="http://www.legislation.gov.uk/eur/2016/1933/pdfs/eur_20161933_adopted_en.pdf" Date="2016-11-05" Size="325008"/></ukm:Alternatives><ukm:Statistics><ukm:TotalParagraphs Value="2"/><ukm:BodyParagraphs Value="2"/><ukm:ScheduleParagraphs Value="0"/><ukm:AttachmentParagraphs Value="0"/><ukm:TotalImages Value="0"/></ukm:Statistics></proprietary></meta><preface eId="preface"><longTitle><p>
               <inline name="uppercase">Commission Implementing Regulation</inline> (EU) 2016/1933</p><p>of 4 November 2016</p><p>approving calcium magnesium tetrahydroxide (hydrated dolomitic lime) as an existing active substance for use in biocidal products of product-types 2 and 3</p><p>(Text with EEA relevance)</p></longTitle></preface><preamble><p>THE EUROPEAN COMMISSION,</p><p>Having regard to the Treaty on the Functioning of the European Union,</p><p>Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products<authorialNote class="footnote" eId="f00001" marker="1"><p>
                  <ref eId="c00001" href="https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2012.167.01.0001.01.ENG">OJ L 167, 27.6.2012, p. 1</ref>.</p></authorialNote>, and in particular the third subparagraph of Article 89(1) thereof,</p><p>Whereas:</p><blockContainer class="division" uk:name="division"><num>(1)</num><p>Commission Delegated Regulation (EU) No 1062/2014<authorialNote class="footnote" eId="f00002" marker="2"><p>Commission Delegated Regulation (EU) No 1062/2014 of 4 August 2014 on the work programme for the systematic examination of all existing active substances contained in biocidal products referred to in Regulation (EU) No 528/2012 of the European Parliament and of the Council (<ref eId="c00002" href="https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2014.294.01.0001.01.ENG">OJ L 294, 10.10.2014, p. 1</ref>).</p></authorialNote> establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes calcium magnesium tetrahydroxide (hydrated dolomitic lime).</p></blockContainer><blockContainer class="division" uk:name="division"><num>(2)</num><p>Calcium magnesium tetrahydroxide (hydrated dolomitic lime) has been evaluated in accordance with Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council<authorialNote class="footnote" eId="f00003" marker="3"><p>Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (<ref eId="c00003" href="https://webarchive.nationalarchives.gov.uk/eu-exit/https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.1998.123.01.0001.01.ENG">OJ L 123, 24.4.1998, p. 1</ref>).</p></authorialNote> for use in products of product-type 2, disinfectants and algaecides not intended for direct application to humans or animals, and product-type 3, veterinary hygiene, as described in Annex V to that Directive, which correspond to product-types 2 and 3 respectively, as described in Annex V to Regulation (EU) No 528/2012.</p></blockContainer><blockContainer class="division" uk:name="division"><num>(3)</num><p>The United Kingdom was designated as evaluating competent authority and submitted the assessment reports together with its recommendations on 19 September 2011.</p></blockContainer><blockContainer class="division" uk:name="division"><num>(4)</num><p>In accordance with Article 7(2) of Delegated Regulation (EU) No 1062/2014, the opinions of the European Chemicals Agency were formulated on 14 April 2016 by the Biocidal Products Committee, having regard to the conclusions of the evaluating competent authority.</p></blockContainer><blockContainer class="division" uk:name="division"><num>(5)</num><p>According to those opinions, biocidal products of product-types 2 and 3 and containing calcium magnesium tetrahydroxide (hydrated dolomitic lime) may be expected to satisfy the requirements of Article 5 of Directive 98/8/EC, provided that certain specifications and conditions concerning their use are complied with.</p></blockContainer><blockContainer class="division" uk:name="division"><num>(6)</num><p>It is therefore appropriate to approve calcium magnesium tetrahydroxide (hydrated dolomitic lime) for use in biocidal products of product-types 2 and 3, subject to compliance with certain specifications and conditions.</p></blockContainer><blockContainer class="division" uk:name="division"><num>(7)</num><p>A reasonable period should be allowed to elapse before an active substance is approved in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.</p></blockContainer><blockContainer class="division" uk:name="division"><num>(8)</num><p>The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,</p></blockContainer><p>HAS ADOPTED THIS REGULATION:</p></preamble><body eId="body"><article eId="article-1"><num>Article 1</num><content><p>Calcium magnesium tetrahydroxide (hydrated dolomitic lime) is approved as an active substance for use in biocidal products of product-types 2 and 3, subject to the specifications and conditions set out in the Annex.</p></content></article><article eId="article-2"><num>Article 2</num><content><p>This Regulation shall enter into force on the twentieth day following that of its publication in the <i>Official Journal of the European Union</i>.</p></content></article><hcontainer name="signatures"><intro><p>This Regulation shall be binding in its entirety and directly applicable in all Member States.</p></intro><hcontainer name="signatureBlock"><content><p>Done at Brussels, 4 November 2016.</p><p>
                        <i>For the Commission</i>
                     </p><p>
                        <i>The President</i>
                     </p><p>Jean-Claude <inline name="uppercase">Juncker</inline>
                     </p></content></hcontainer></hcontainer><hcontainer name="schedules" eId="schedules"><hcontainer name="schedule" eId="annex"><num>ANNEX</num><content><tblock class="table" ukl:Orientation="landscape"><foreign><table xmlns="http://www.w3.org/1999/xhtml"><tbody><tr><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Common Name</p></th><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">IUPAC NameIdentification Numbers</p></th><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Minimum degree of purity of the active substance<authorialNote class="tablenote" eId="f00004" marker="4"><p>The purity indicated in this column was the minimum degree of purity of the active substance evaluated in accordance with Article 89(1) of Regulation (EU) No 528/2012. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.</p></authorialNote></p></th><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Date of approval</p></th><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Expiry date of approval</p></th><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Product type</p></th><th><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Specific conditions</p></th></tr><tr><td rowspan="2"><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Calcium magnesium tetrahydroxide (hydrated dolomitic lime)</p></td><td rowspan="2"><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">IUPAC Name:</p><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">Calcium magnesium tetrahydroxide</p><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">EC No: 254-454-1</p><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">CAS No: 39445-23-3</p></td><td rowspan="2"><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">800 g/kg</p><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">(The value provides the content of Ca and Mg expressed as Ca(OH)<sub>2</sub> and Mg(OH)<sub>2</sub>. Typical values for Mg(OH)<sub>2</sub> in hydrated dolomitic lime are in the range of 15 %-40 %)</p></td><td rowspan="2"><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">1 May 2018</p></td><td rowspan="2"><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">30 April 2028</p></td><td><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">2</p></td><td><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">The authorisations of biocidal products are subject to the following conditions:</p><blockList xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0" class="ordered arabic parens" ukl:Name="OrderedList" ukl:Type="arabic" ukl:Decoration="parens"><item><num>(1)</num><p>The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.</p></item><item><num>(2)</num><p>In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to industrial and professional users.</p></item></blockList></td></tr><tr><td><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">3</p></td><td><p xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">The authorisations of biocidal products are subject to the following conditions:</p><blockList xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0" class="ordered arabic parens" ukl:Name="OrderedList" ukl:Type="arabic" ukl:Decoration="parens"><item><num>(1)</num><p>The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.</p></item><item><num>(2)</num><p>In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to professional users.</p></item></blockList></td></tr></tbody></table></foreign></tblock></content></hcontainer></hcontainer></body></act></akomaNtoso>